Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Century Therapeutics (IPSC) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to 70.12%.

  • Century Therapeutics' EBITDA Margin rose 33930400.0% to 70.12% in Q1 2025 from the same period last year, while for Sep 2025 it was 23.97%, marking a year-over-year increase of 47368800.0%. This contributed to the annual value of 1917.59% for FY2024, which is 40825400.0% up from last year.
  • According to the latest figures from Q1 2025, Century Therapeutics' EBITDA Margin is 70.12%, which was up 33930400.0% from 874.84% recorded in Q4 2024.
  • Century Therapeutics' 5-year EBITDA Margin high stood at 70.12% for Q1 2025, and its period low was 33558.59% during Q2 2023.
  • Its 4-year average for EBITDA Margin is 7454.87%, with a median of 3733.93% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -312820800bps in 2023, then surged by 295021700bps in 2024.
  • Quarter analysis of 4 years shows Century Therapeutics' EBITDA Margin stood at 5861.8% in 2022, then tumbled by -142bps to 14173.13% in 2023, then soared by 94bps to 874.84% in 2024, then skyrocketed by 108bps to 70.12% in 2025.
  • Its EBITDA Margin stands at 70.12% for Q1 2025, versus 874.84% for Q4 2024 and 3812.77% for Q3 2024.